|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
Véronique Leblond
,
Pierre Morel
,
Marie-Sarah Dilhuidy
,
Xavier Leleu
,
Carole Soussain
et al.
Journal articles
hal-01655961v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
Guillaume Cartron
,
Remi Letestu
,
Caroline Dartigeas
,
Mira Tout
,
Beatrice Mahe
et al.
Journal articles
hal-01860398v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial
Arnaud Pigneux
,
Marie Béné
,
Louis-Rachid Salmi
,
Pierre-Yves Dumas
,
Jacques Delaunay
et al.
Journal articles
hal-02874606v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Anne-Sophie Michallet
,
Marie-Sarah Dilhuydy
,
Fabien Subtil
,
Valérie Rouillé
,
Béatrice Mahé
et al.
Journal articles
hal-02299505v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Anne-Laure Gagez
,
Isabelle Duroux-Richard
,
Stéphane Leprêtre
,
Frédérique Orsini-Piocelle
,
Rémi Letestu
et al.
Journal articles
hal-01568353v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL
Norbert Schmitz
,
Lorenz Truemper
,
Krimo Bouabdallah
,
Marita Ziepert
,
Mathieu Leclerc
et al.
Journal articles
hal-03163608v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)
Thierry Lamy
,
Gandhi Damaj
,
Pierre Soubeyran
,
Emmanuel Gyan
,
Guillaume Cartron
et al.
Journal articles
hal-01635792v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
Arnaud Pigneux
,
Christian Récher
,
Marie C. Bene
,
Julien Asselineau
,
Ariane C. Mineur
et al.
Blood, 2015, 126 (23)
Journal articles
hal-01295674v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|